title: Pilot study of PCNU and cranial radiation therapy in the treatment of patients with malignant gliomas.
abstract: A pilot study was performed administering PCNU with radiation therapy to treat patients with high-grade astrocytomas and to explore the toxic effects of this drug regimen. PCNU at an initial dose of 110 mg/m2 i.v. was administered to 14 patients within 4 weeks after completion of cranial irradiation. Courses were repeated every 6-8 weeks upon recovery from myelosuppression. Radiation therapy consisted of 5,000 rad to the whole brain followed by an additional 1,500 rad to the tumor site. Patients were followed by CT scan and neurologic examination. The median survival for the group was 80 weeks. Larger, randomized trials comparing PCNU to other nitrosoureas will be needed to assess its value as adjuvant therapy in patients with malignant gliomas. Myelosuppression, particularly, thrombocytopenia, was the main toxic effect in this study. Pulmonary infiltrates developed in 2 patients and was progressive and fatal in 1 patient after a total cumulative PCNU dose of 850 mg/m2. Hepatic dysfunction with hyperbilirubinemia also developed in 1 patient. PCNU can produce pulmonary and hepatic toxicity similar to that reported for other nitrosoureas. Regular monitoring of pulmonary and hepatic function tests should be performed during treatment with PCNU in future trials.
authors.affiliation: Section of Neurology, University of Texas System Cancer Center, MD Anderson Hospital and Tumor Institute, Houston.
authors.forename: L G
authors.initials: LG
authors.lastname: Feun
authors.forename: M
authors.initials: M
authors.lastname: Maor
authors.forename: D J
authors.initials: DJ
authors.lastname: Stewart
authors.forename: M E
authors.initials: ME
authors.lastname: Leavens
authors.forename: N
authors.initials: N
authors.lastname: Savaraj
authors.forename: G P
authors.initials: GP
authors.lastname: Bodey
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001254:Astrocytoma / Q000188:drug therapy / Q000532:radiotherapy; D003131:Combined Modality Therapy / Q000009:adverse effects; D005260:Female; D005909:Glioblastoma / Q000188:drug therapy / Q000532:radiotherapy; D005910:Glioma / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy / Q000628:therapy*; D006801:Humans; D008875:Middle Aged; D009607:Nitrosourea Compounds / Q000627:therapeutic use*; D010865:Pilot Projects
chemical_list: D000970:Antineoplastic Agents; D009607:Nitrosourea Compounds; C018627:1-(2-chloroethyl)-3-(2,6-dioxo-3-piperidinyl)-1-nitrosourea